Lead – In November 2026, Proximal Ventures announced the closing of a $27.5 million debut venture fund aimed at early‑stage companies that apply artificial intelligence to pharmaceutical services, according to TechCrunch. The fund, raised by former SignalFire investor Sahir Raoof, will write checks ranging from $500,000 to $1.5 million and has already backed seven startups, including ChronicleBio, co‑founded by former OpenAI executive Fidji Simo.
Fundraising in a tight market
According to TechCrunch, first‑time fund managers are encountering “one of the toughest fundraising environments in years,” yet Raoof succeeded in securing capital despite the broader slowdown. The limited partners (LPs) that committed to the fund include venture firms SignalFire and Kleiner Perkins, Bertelsmann Healthcare Investments, and individual investors such as Dimension Capital co‑founders Nan Li and Zavain Dar.
Investment thesis: AI can reshape pharma services
Raoof’s thesis, as reported by TechCrunch, is that artificial intelligence can automate many of the service‑oriented tasks traditionally outsourced by pharmaceutical companies. Historically, pharma has been “a really good buyer of services” rather than software, Raoof told TechCrunch. By applying AI to functions such as molecular synthesis, scale‑up manufacturing planning, and clinical‑trial data analysis, startups could deliver comparable outcomes at lower cost and faster speed, potentially unlocking billions of dollars of industry spend.
The article notes that AI’s most valuable applications to date have been in other service‑heavy sectors like law and finance, and Raoof believes the pharmaceutical services market offers a comparable opportunity.
Target stage and check size
According to TechCrunch, Proximal Ventures will focus on pre‑seed and seed‑stage companies, writing investments between $500,000 and $1.5 million. The fund’s early portfolio already includes seven startups, the most prominent being ChronicleBio, which uses AI to analyze biological and medical data to better understand chronic diseases and identify treatment candidates. ChronicleBio’s co‑founder, Fidji Simo, previously held an executive role at OpenAI, as noted by TechCrunch.
Raoof’s background and LP confidence
TechCrunch reports that Raoof’s credibility with LPs stems from a blend of venture, operational, and partnership experience in the life‑sciences ecosystem. Prior to launching Proximal, he spent two years as a principal at SignalFire and previously led business development at clinical‑trial recruitment startup Iterative Health. He also oversaw partnerships at Flatiron Health, an oncology data company acquired by Roche for $1.9 billion in 2018.
Raoof told TechCrunch that “building a company that’s selling into the life sciences… the hardest thing is starting that initial commercial flywheel.” His sales expertise and extensive industry network, according to TechCrunch, reassured LPs that he could both identify promising startups and help them secure early customers.
Notable investors and endorsements
Among the fund’s backers, Amy Abernethy—co‑founder of Highlander Health and former principal deputy commissioner of the FDA—has publicly endorsed Raoof’s approach. TechCrunch reports that Abernethy first met Raoof at Flatiron Health, where she served as chief medical officer. She said his ability to build relationships and spot industry bottlenecks left a lasting impression, and she believes those qualities, combined with a clear view of market needs, position him for success as an investor.
Outlook and market impact
Opinion: While the article does not provide performance metrics, the combination of a sizable first fund, a focused AI‑in‑pharma thesis, and backing from established venture firms suggests Proximal Ventures could become a notable early‑stage player in a market that is still largely service‑driven. If AI can indeed deliver cost and time efficiencies as Raoof envisions, the fund’s portfolio may attract follow‑on capital from larger biotech and pharma investors seeking to modernize their service supply chains.
Conclusion
Proximal Ventures’ $27.5 million debut fund represents a strategic bet on artificial intelligence to modernize the pharmaceutical services ecosystem. Backed by a roster of prominent venture firms and industry veterans, the fund will target pre‑seed and seed startups with check sizes of $500,000 to $1.5 million, aiming to capture a share of the billions spent on outsourced drug‑development activities.
Source: TechCrunch
Frequently Asked Questions
How much capital did Proximal Ventures raise for its first fund?
Proximal Ventures raised $27.5 million for its debut venture fund, according to TechCrunch.
What stage companies does Proximal plan to invest in, and what is the typical investment size?
The firm will target pre‑seed and seed‑stage startups, writing checks between $500,000 and $1.5 million, as reported by TechCrunch.
Which notable startup in Proximal’s portfolio uses AI to analyze chronic disease data?
ChronicleBio, co‑founded by former OpenAI executive Fidji Simo, uses AI to analyze biological and medical data for chronic disease research, according to TechCrunch.